Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. to develop mGluR2PAM compounds for the treatment of human health; and research collaboration agreement with Indivior PLC. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
IPO Year:
Exchange: NASDAQ
Website: addextherapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/31/2024 | $30.00 | Neutral → Buy | H.C. Wainwright |
| 2/11/2022 | $28.00 → $21.00 | Buy | HC Wainwright & Co. |
6-K - Addex Therapeutics Ltd. (0001574232) (Filer)
20-F - Addex Therapeutics Ltd. (0001574232) (Filer)
6-K - Addex Therapeutics Ltd. (0001574232) (Filer)
NT 20-F - Addex Therapeutics Ltd. (0001574232) (Filer)
6-K - Addex Therapeutics Ltd. (0001574232) (Filer)
6-K - Addex Therapeutics Ltd. (0001574232) (Filer)
6-K - Addex Therapeutics Ltd. (0001574232) (Filer)
6-K - Addex Therapeutics Ltd. (0001574232) (Filer)
6-K - Addex Therapeutics Ltd. (0001574232) (Filer)
6-K - Addex Therapeutics Ltd. (0001574232) (Filer)
H.C. Wainwright upgraded Addex Therapeutics from Neutral to Buy and set a new price target of $30.00
HC Wainwright & Co. reiterated coverage of Addex Therapeutics with a rating of Buy and set a new price target of $21.00 from $28.00 previously
HC Wainwright & Co. initiated coverage of Addex Therapeutics with a rating of Buy and set a new price target of $28.00
Strong cash position of CHF2.8 million at end of Q1 2025GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to our phase 2 mGlu2 PAM asset, ADX71149Indivior advanced GABAB PAM Substance use disorders program successfully through IND enabling studiesEntered option agreement with Sinntaxis for an exclusive license to intellectual property covering the use of mGlu5 NAM in brain injury recovery Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 19, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators
Geneva, Switzerland, June 18, 2025 - Addex Therapeutics (SIX/NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will issue its Q1 2025 Financial Results on June 19, 2025. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) the same day. Title: Addex Therapeutics Q1 2025 financial results and corporate update Date: June 19, 2025Time: 16:00 CEST (15:
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 6, 2025 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today robust anti-tussive activity of its novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) in multiple preclinical models of chronic cough compared to reference drugs. Some of these preclinical data with Addex GABAB PAM drug candidate will be presented on June 7, 2025 at the 10th American Cough Conference, in Dulles, Virginia by Dr Mikhail Kalinichev, Head of Translational S
Geneva, Switzerland, June 5, 2025 - Addex Therapeutics (SIX/NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that preclinical data from its gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) cough program will be presented at the 10th American Cough Conference (June 6-7) in Dulles, VA. A presentation given by Mikhail Kalinichev, Head of Translational Science at Addex will describe the progress seen to date with the Addex GABAB PAM cough program, including antitussive data from in vivo models. Addex lead drug candidate is re
Geneva, Switzerland, June 3, 2025 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its 2025 Annual General Meeting will take place on Tuesday June 24, 2025, at 11:00 am CEST at the Campus Biotech, Chemin des Mines 9, 1202 Geneva (doors open at 10:30 am). Agenda 1. Approval of the Annual Report, the Annual Financial Statements and the Consolidated Financial Statements for the business year 20242. Consultative vote on the Compensation Report for the business year 20243. Appropriation of the results4. Discharge of the members of
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 12, 2025 - Addex Therapeutics (SIX/NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today partner Indivior has successfully advanced its GABAB positive allosteric modulator (PAM) program through IND enabling studies. This is the final preclinical development stage before clinical studies can be started. "Our partner Indivior has made great progress with their GABAB PAM substance use disorders program, successfully completing the last preclinical safety and toxicity studies with the compound they se
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 30, 2025 - Addex Therapeutics (SIX/NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that it has entered into an option- and collaboration agreement with Sinntaxis AB (www.sinntaxis.com) for an exclusive license to intellectual property covering the use of metabotropic glutamate receptor subtype 5 (mGlu5) inhibitors for the treatment of brain injury recovery. The agreement also includes a research collaboration under which the Sinntaxis team will complete evaluation of Addex's dipraglurant, an
Launched Neurosterix with Perceptive Advisors, raising USD 65 million in Series A to advance preclinical portfolioIndivior selected GABAB PAM drug candidate and started IND enabling studies for development in substance use disordersAddex selected independent GABAB PAM drug candidate for development in chronic coughRepositioned our phase 2 mGlu5 NAM asset, dipraglurant in brain injury recoveryRegained rights to our phase 2 mGlu2 PAM asset, ADX71149 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 25, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators
Geneva, Switzerland, April 24, 2025 - Addex Therapeutics (SIX/NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will issue its Full-Year 2024 Financial Results on April 25, 2025. Tim Dyer, CEO, and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) the same day. Title: Addex Therapeutics Full-Year 2024 financial results and corporate update Date: April 25, 2025Ti
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 17, 2025 - Addex Therapeutics (SIX/NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that following the previously announced termination of development of ADX71149 (JNJ-40411813) in epilepsy, its partner Janssen Pharmaceuticals, Inc. (now known as J&J Innovative Medicine) has return all development and commercialization rights to ADX71149 (JNJ-40411813) and the partnership between the two companies has been terminated. "ADX71149 is a high quality asset which has completed three Phase 2 studi
Strong cash position of CHF2.8 million at end of Q1 2025GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to our phase 2 mGlu2 PAM asset, ADX71149Indivior advanced GABAB PAM Substance use disorders program successfully through IND enabling studiesEntered option agreement with Sinntaxis for an exclusive license to intellectual property covering the use of mGlu5 NAM in brain injury recovery Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 19, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators
Geneva, Switzerland, June 18, 2025 - Addex Therapeutics (SIX/NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will issue its Q1 2025 Financial Results on June 19, 2025. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) the same day. Title: Addex Therapeutics Q1 2025 financial results and corporate update Date: June 19, 2025Time: 16:00 CEST (15:
Launched Neurosterix with Perceptive Advisors, raising USD 65 million in Series A to advance preclinical portfolioIndivior selected GABAB PAM drug candidate and started IND enabling studies for development in substance use disordersAddex selected independent GABAB PAM drug candidate for development in chronic coughRepositioned our phase 2 mGlu5 NAM asset, dipraglurant in brain injury recoveryRegained rights to our phase 2 mGlu2 PAM asset, ADX71149 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 25, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators
Geneva, Switzerland, April 24, 2025 - Addex Therapeutics (SIX/NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will issue its Full-Year 2024 Financial Results on April 25, 2025. Tim Dyer, CEO, and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) the same day. Title: Addex Therapeutics Full-Year 2024 financial results and corporate update Date: April 25, 2025Ti
Indivior selected GABA B PAM drug candidate for development in substance use disorders (SUD) and starts IND enabling studies Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 22, 2024 - Addex Therapeutics (SIX/NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its third quarter financial results for the periods ended September 30, 2024, and provided a corporate update. "During the third quarter of 2024, Indivior selected a GABAB PAM drug candidate from our collaboration for development in substance use disorders, allowing us to select our
Nine-month Results Remain On Track for Net Profit Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 11, 2024 - Addex Therapeutics (SIX/NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its provisional third quarter net results decreased significantly compared to the second quarter 2024. The provisional result for the third quarter of 2024 show a net loss of CHF 1.5 million compared to a net profit of CHF 12.9 million for the second quarter of 2024. The decrease of CHF 14.4 million is primarily due to the sale of part of the Addex b
Launched Neurosterix with Perceptive Advisors to accelerate the development of M4PAM for schizophreniaIndivior selected GABA B PAM drug candidate for development in substance use disordersAddex selected independent GABAB PAM drug candidate for development in chronic cough Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 30, 2024 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its half-year and second quarter financial results for the periods ended June 30, 2024, and provided a corporate update.
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 19, 2024 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its provisional half-year and second quarter net results have increased significantly in 2024 compared to 2023 and first quarter 2024 results primarily due to the sale of part of its business to Neurosterix Pharma Sàrl on April 2, 2024. The provisional result amount to a net gain of CHF 9.8 million for the six-month period ended June 30, 2024 compared to a net loss of CHF 5.1 million for the six
● GABAB PAM: Selection of drug candidates under Indivior collaboration expected by end of Q2 2024. Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 6, 2024 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its Q1 2024 financial results and provided a corporate update. "Building on the recent Neurosterix transaction, which extended our cash runway beyond 2026 and will accelerate the development of a portfolio of preclinical programs, we anticipate selection of drug candidates under the agreement w
Geneva, Switzerland, May 31, 2024 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that it will issue its Q1 2024 Financial Results on June 6, 2024. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and a review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) the same day. Title: Addex Therapeutics to release Q1 2024 financial results and provides corporate update Date: June 6, 2024Time: 16
Geneva, Switzerland, August 2, 2021 (GLOBE NEWSWIRE) - Ad Hoc Announcement Pursuant to Art. 53 LR Addex Therapeutics Ltd (NASDAQ:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced the appointment of Mikhail Kalinichev, PhD, as Head of Translational Science. Dr. Kalinichev is a seasoned pharmaceutical R&D professional with more than 20 years of diversified experience at leading pharmaceutical companies and academic institutions in France, Denmark, Switzerland, UK and USA. "It's great to have Mikhail back on the Addex team! He is an accomplished neuropharma researcher and drug developer who already knows Addex
SC 13D/A - Addex Therapeutics Ltd. (0001574232) (Subject)
SC 13D/A - Addex Therapeutics Ltd. (0001574232) (Subject)
SC 13D/A - Addex Therapeutics Ltd. (0001574232) (Subject)
SC 13D/A - Addex Therapeutics Ltd. (0001574232) (Subject)
SC 13D/A - Addex Therapeutics Ltd. (0001574232) (Subject)
SC 13D/A - Addex Therapeutics Ltd. (0001574232) (Subject)
SC 13D/A - Addex Therapeutics Ltd. (0001574232) (Subject)
SC 13G/A - Addex Therapeutics Ltd. (0001574232) (Subject)
SC 13G/A - Addex Therapeutics Ltd. (0001574232) (Subject)
SC 13G/A - Addex Therapeutics Ltd. (0001574232) (Subject)